Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)
Patients who undergo upfront curative intent resection for locally advanced squamous cell carcinomas and who have adverse pathologic features benefit from adjuvant therapy. Concurrent cisplatin based chemoradiation is an established standard of care endorsed by national guidelines. Controversy now e...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00588/full |
id |
doaj-9a36d990c48548a7a63c65312e6e858c |
---|---|
record_format |
Article |
spelling |
doaj-9a36d990c48548a7a63c65312e6e858c2020-11-24T21:11:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2018-12-01810.3389/fonc.2018.00588429087Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC)Kedar Kirtane0Cristina P. Rodriguez1Moffitt Cancer Center, Tampa, FL, United StatesDivision of Oncology, Department of Medicine, University of Washington, Seattle, WA, United StatesPatients who undergo upfront curative intent resection for locally advanced squamous cell carcinomas and who have adverse pathologic features benefit from adjuvant therapy. Concurrent cisplatin based chemoradiation is an established standard of care endorsed by national guidelines. Controversy now exists on the applicability of this strategy to the good risk human papilloma virus (HPV) related oropharynx cancer (OPC) patient. Ongoing clinical studies are exploring therapeutic de-escalation in the postoperative setting for this distinct patient population. The introduction of immune checkpoint inhibitors to the therapeutic armamentarium for recurrent/metastatic head and neck cancer patients has led to clinical investigation of incorporation of PD-1 inhibition in the postoperative setting.https://www.frontiersin.org/article/10.3389/fonc.2018.00588/fullhead and neck cancersquamous cell carcinomaHPVhead and neckoropharyngeal carcinomanasopharyngeal carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kedar Kirtane Cristina P. Rodriguez |
spellingShingle |
Kedar Kirtane Cristina P. Rodriguez Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) Frontiers in Oncology head and neck cancer squamous cell carcinoma HPV head and neck oropharyngeal carcinoma nasopharyngeal carcinoma |
author_facet |
Kedar Kirtane Cristina P. Rodriguez |
author_sort |
Kedar Kirtane |
title |
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) |
title_short |
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) |
title_full |
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) |
title_fullStr |
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) |
title_full_unstemmed |
Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC) |
title_sort |
postoperative combined modality treatment in high risk resected locally advanced squamous cell carcinomas of the head and neck (hnscc) |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2018-12-01 |
description |
Patients who undergo upfront curative intent resection for locally advanced squamous cell carcinomas and who have adverse pathologic features benefit from adjuvant therapy. Concurrent cisplatin based chemoradiation is an established standard of care endorsed by national guidelines. Controversy now exists on the applicability of this strategy to the good risk human papilloma virus (HPV) related oropharynx cancer (OPC) patient. Ongoing clinical studies are exploring therapeutic de-escalation in the postoperative setting for this distinct patient population. The introduction of immune checkpoint inhibitors to the therapeutic armamentarium for recurrent/metastatic head and neck cancer patients has led to clinical investigation of incorporation of PD-1 inhibition in the postoperative setting. |
topic |
head and neck cancer squamous cell carcinoma HPV head and neck oropharyngeal carcinoma nasopharyngeal carcinoma |
url |
https://www.frontiersin.org/article/10.3389/fonc.2018.00588/full |
work_keys_str_mv |
AT kedarkirtane postoperativecombinedmodalitytreatmentinhighriskresectedlocallyadvancedsquamouscellcarcinomasoftheheadandneckhnscc AT cristinaprodriguez postoperativecombinedmodalitytreatmentinhighriskresectedlocallyadvancedsquamouscellcarcinomasoftheheadandneckhnscc |
_version_ |
1716753206085681152 |